食管癌术后放疗同步紫杉醇+奈达铂方案治疗效果研究.doc

食管癌术后放疗同步紫杉醇+ 奈达铂方案治疗效果研究【摘要】目的:了解放?? 同步紫杉醇+ 奈达铂方案对食管癌术后患者的治疗效果及安全性。方法:以 2012 年1月-2014 年1 月入院治疗且接受过手术切除的 124 例患者为研究对象,将患者随机分为同步放化疗组与单纯放疗组,各 62 例。单纯放疗组只采取单纯的放疗治疗,同步放化疗组在放射治疗的同时给予紫杉醇+ 奈达铂化疗方案, 观察比较两组患者的不良反应发生率、总生存率( OS) 、无疾病生存率( DFS )、局部无复发生存率( LRFS ) 及无远处转移生存率( DMFS )。结果: 同步放化疗组的白细胞下降、胃肠道反应发生率均高于单纯放疗组,差异均有统计学意义( x2= , P= ; x2= , P= )。同步放化疗组 3 年生存率高于单纯放疗组, 差异有统计学意义( x2= , P= )。同步放化疗组接受R0 手术的患者3年 DFS 高于单纯放疗组, 差异有统计学意义( x2= , P= ) 。同步放化疗组的 1、3年 LRFS 均高于单纯放疗组, 差异均有统计学意义( x2= , P= ; x2= , P= )。同步放化疗组 3年 DMFS 高于单纯放疗组, 差异有统计学意义( x2= , P= ) 。同步放化疗组累计出现 28例( % )治疗失败,单纯放疗组累计出现 45 例( % )治疗失败, 单纯放疗组治疗失败的比例高于同步放化疗组,差异有统计学意义( x2= , P= ) 。结论:食管癌术后放疗同步紫杉醇+ 奈达铂方案可有效改善患者预后,提高患者生存率,延长生存时间,且有着较高的安全性,可在临床上进行推广。本文采集自网络,本站发布的论文均是优质论文,版权和著作权归原作者所有。【关键词】食管癌; 同步放化疗; 生存率; 预后 Study on the Effect of Concurrent Paclitaxel + Nedaplatin in Postoperative Radiotherapy for Esophageal Carcinoma/KANG Zhao-jun.//Medical Innovation of China , 2017 , 14( 12): 032-036 【 Abstract 】 Objective : To evaluate the efficacy and safety of bined with Paclitaxel+Nedaplatin in patients with postoperative esophageal :A total of 124 patients who underwent surgical resection in our hospital from January 2012 to January 2014 were enrolled in the study , the patients were divided into concurrent chemoradiotherapy group and simple radiotherapy group , 62 cases in each simple radiotherapy group was treated with radiotherapy alone , the concurrent chemoradiotherapy group was treated with Paclitaxel plus Nedaplatin incidence of adverse reactions , overall survival , disease-free survival , local recurrence free survival and distant metastasis free survival were observed pared between the two groups. Result : The incidence of leukopenia and gastrointestinal reaction in concurrent chemoradiotherapy group were higher those of simple radiotherapy group , the differences were statistically significant ( x